CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02647762
• Other study ID #: CF101-301RA
• Status: Terminated
• Phase: Phase 3
• Start date: October 30, 2017
• Est. completion date: November 30, 2020

Study information

• Verified date: March 2020
• Source: Can-Fite BioPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.

Description:

This will be a randomized, double-blind, active- and placebo-controlled, parallel-group study in subjects with clinically active RA but who are MTX-naïve. Subjects who meet enrollment criteria will be randomized to 1 of 4 groups in a 2:2:2:1 ratio: CF101 1 mg, CF101 2 mg, MTX, or matching placebo tablets. CF101 or matching placebo will be administered every 12 hours for up to 24 weeks on treatment. MTX or matching placebo will be administered once a week Screening examinations will occur within 6 weeks prior to dosing. The following conventional drugs for RA treatment must be stable for the respective designated periods prior to the Screening Visit and must remain so during protocol participation: nonsteroidal anti-inflammatory drugs (NSAIDS), and corticosteroids for >1 month. All subjects will receive oral folate (minimum dose 5 mg/week) or oral folinic acid (up to 10 mg/week), based on the Investigator's preference.

Disease activity will be assessed using swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and CRP. Efficacy will be assessed by Disease Activity Score 28 using the erythrocyte sedimentation rate (DAS28-ESR), ACR response criteria and European League Against Rheumatism (EULAR) response criteria : swollen and tender joint counts, physician global assessment (by visual analog scale, patient global assessment , patient reported pain, a Health Assessment Questionnaire (HAQ) Disability Index (DI) , Westergren ESR levels, and CRP levels. Assessments will occur at Screening, Baseline (Week 0), and Weeks 4, 8, 12 16, 20, and 24. At Weeks 12, 16, and 20, any subject who has not experienced at least 20% improvement in both the number of swollen and number of tender joints will be given rescue therapy with open-label oral MTX and followed through Week 24.

PK will be assessed in a subgroup of approximately 100 subjects at Week 0, Week 8, and Week

12. All subjects in the PK cohort will have samples collected for PK at time 0, and each subject will have additional samples drawn at 2 of the following post-dose time points: 1, 2, 3, 4, 6, and 8 hours. Whole blood sample for A3AR expression will be assessed in approximately 100 subjects at selected sites at Screening and Week 12, or end of dosing, if occurring before Week 12.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 244
• Est. completion date: November 30, 2020
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Males and females ages 18-75 years.

2. Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324, Appendix 1).

3. Not bed- or wheelchair-bound.

4. Active RA, as indicated by EULAR Disease Activity Score (Fransen, vanRiel, 2005, DAS28, 2015) (DAS28) >3.2.

5. Demonstrate at least 6 swollen and at least 6 tender joints.

6. If taking an NSAID, dose has been stable for at least 1 month prior to the Screening Visit, and will remain unchanged during protocol participation.

7. If taking an oral corticosteroid, dose is <10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the Screening Visit, and will remain unchanged during protocol participation.

8. In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.

9. Negative Screening serum pregnancy test for female subjects of childbearing potential.

10. Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method).

11. All aspects of the protocol explained and written informed consent obtained.

Exclusion Criteria:

1. Prior receipt of MTX.

2. Prior receipt of >1 regimen of synthetic small-molecule DMARDs.

3. Receipt of any non-MTX synthetic small-molecule DMARDs (including but not limited to sulfasalazine, chloroquine/hydroxychloroquine, azathioprine, and/or leflunomide) for at least 1 month prior to the Screening Visit or concomitantly during the trial.

4. Receipt of tofacitinib at any time during the 4-week period prior to the Screening Visit or concomitantly during the trial.

5. Receipt of a biologic anti-rheumatic agent (including, but not limited to, etanercept, abatacept, infliximab, golimumab, adalimumab, tocilizumab, certolizumab, and rituximab) at any time prior to or concomitantly during the trial.

6. Levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody that are both >3 times the upper limit of the laboratory normal value at the Screening Visit.

7. Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to the Screening Visit.

8. Participation in a previous trial CF101 trial.

9. Presence or history of uncontrolled arterial hypertension or symptomatic hypotension.

10. Heart disease which is, in the Investigator's judgment, clinically significant or unstable, including coronary artery disease, congestive heart failure, uncontrolled arrhythmia, or other significant findings on Screening electrocardiogram (ECG).

11. Clinical laboratory abnormalities at the Screening Visit as follows:

1. Hemoglobin level <9.0 gm/dL

2. Platelet count <125,000/mm3

3. White blood cell (WBC) count <3000/mm3

4. Serum creatinine level outside the central laboratory's normal limits

5. Liver aminotransferase (ALT and/or AST) levels greater than 2 times the central laboratory's upper limit of normal.

12. Known or suspected immunodeficiency or human immunodeficiency virus positivity.

13. Pregnancy, lactation, or inadequate contraception as judged by the Investigator.

14. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening.

15. Active drug or alcohol dependence.

16. History of malignancy within the past 2 years (excluding excised basal or squamous cell carcinoma of the skin).

17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• CF101 1 mg
CF101 tablets, 1mg BID for 12 weeks
• CF101 2 mg
CF101 tablets, 2 mg BID for 12 weeks
• Placebo
Placebo tablets, 1mg BID for 12 weeks
• MTX
MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.

Locations

Country	Name	City	State
Bosnia and Herzegovina	Can-Fite Investigational Site #252	Banja Luka
Bosnia and Herzegovina	Can-Fite Investigational Site #256	Banja Luka
Bosnia and Herzegovina	Can-Fite Investigational Site #253	Mostar
Bosnia and Herzegovina	Can-Fite Investigational Site #251	Sarajevo
Bosnia and Herzegovina	Can-Fite Investigational Site #255	Tuzla
Canada	Can-Fite Investigational Site #751	Barrie
Israel	Can-Fite Investigational Site #309	Ashkelon
Israel	Can-Fite Investigational Site #302	Haifa
Moldova, Republic of	Can-Fite Investigational Site #581	Chisinau
Moldova, Republic of	Can-Fite Investigational Site #582	Chisinau
Moldova, Republic of	Can-Fite Investigational Site #583	Chisinau
Poland	Can-Fite Investigational Site #401	Bialystok
Poland	Can-Fite Investigational Site #402	Bochnia
Poland	Can-Fite Investigational Site #403	Poznan
Romania	Can-Fite Investigational Site #559	Braila
Romania	Can-Fite Investigational Site #551	Bucuresti
Romania	Can-Fite Investigational Site #552	Bucuresti
Romania	Can-Fite Investigational Site #553	Bucuresti
Romania	Can-Fite Investigational Site #562	Bucuresti
Romania	Can-Fite Investigational Site #564	Bucuresti
Romania	Can-Fite Investigational Site #565	Bucuresti
Romania	Can-Fite Investigational Site #558	Constanta
Romania	Can-Fite Investigational Site #563	Craiova
Romania	Can-Fite Investigational Site #561	Iasi
Romania	Can-Fite Investigational Site #555	Oradea
Romania	Can-Fite Investigational Site #554	Timisoara
Serbia	Can-Fite Investigational Site #214	Šabac
Serbia	Can-Fite Investigational Site #212	Belgrad
Serbia	Can-Fite Investigational Site #223	Bor
Serbia	Can-Fite Investigational Site #219	Kragujevac
Serbia	Can-Fite Investigational Site #215	Niš
Serbia	Can-Fite Investigational Site #213	Novi Sad
Serbia	Can-Fite Investigational Site #222	Pirot
Serbia	Can-FIte Investigational Site #221	Sremska Mitrovica
Serbia	Can-Fite Investigational Site #220	Zrenjanin

Sponsors (1)

Lead Sponsor	Collaborator
Can-Fite BioPharma

Countries where clinical trial is conducted

Bosnia and Herzegovina,  Canada,  Israel,  Moldova, Republic of,  Poland,  Romania,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of oral CF101, BID for 12 weeks to subjects with active rheumatoid arthritis (RA) relative to oral methotrexate (MTX) as assessed by the proportion of subjects achieving a Disease Activity Score (DAS) of Low Disease Activity (LDA)	Proportion of subjects achieving Disease Activity Score (DAS) (based on Erythrocyte Sedimentation Rate) of Low Disease Activity (<3.2, where lower scores indicate lower disease activity) at Week 12	12 weeks
Primary	Assess the adverse event profile of daily oral CF101 under the conditions of the trial	Nature, incidence and severity of treatment-emergent adverse events (TEAEs)	24 weeks
Primary	Describe the pharmacokinetics (PK) of CF101 under the conditions of the trial	Plasma CF101 levels will be determined	24 weeks
Secondary	Determine the efficacy of oral CF101 when administered daily for 24 weeks to subjects with active RA relative to oral MTX, as assessed by the proportion of subjects achieving DAS remission	Change and percent change from baseline in DAS28	24 weeks
Secondary	Explore the relationship between whole blood adenosine A3 receptor (A3AR) expression and treatment response	A3AR expression will be assessed on whole blood samples	24 weeks